None listed
Conditions
Interventions
Intervention1: LI89034F2 375 mg: 1 capsule to be taken every morning before breakfast and every night before dinner for 42 days
Control Intervention1: Placebo: 1 capsule to be taken every morning befo
Sponsors
Laila Nutraceuticals
Eligibility
Inclusion criteria
Inclusion criteria: • Male subjects between 18-40 years of age • Ability to understand the risks/benefits of the protocol • Subjects Familiar with weight training and have at least 6 months experience training, 4 times per week for at least 3 to 4 hours. (Recreational athletes) • Agree to do physical activities as stated in the protocol in presence of physical trainer • Willingness to participate in an exercise program (4 days a week, during the course of the study) • Subject should be available for duration of study period (7 weeks) • Subject agrees not to start any new therapies which would affect body composition during the course of the study. • Subjects agree to maintain the dairy activity • Willing to give written informed consent and willing to comply with trial protocol
Exclusion criteria
Exclusion criteria: • No contraindications to exercise as outlined by the American College of Sports Medicine (ACSM) • Use of nutritional supplements known to improve energy and muscle strength and/or muscle mass (e.g., Creatine, HMB, androstenedione, DHEA, etc.) within seven weeks prior to the start of the study • All medications that can interfere with muscle mass such as corticosteroids (e.g. Prednisone), testosterone replacement or anabolic drugs • Subjects who are under herbal supplements within fourteen (14) days prior to screening • Subjects using any other therapies that would affect body composition other than those revealed during recruitment process. • Subjects having history of asthma • Subjects having history of cardiovascular diseases • Subjects having history of diabetes (Type I or Type II) except other than the subject having the pre-diabetes condition with the fasting blood glucose between 100 to 125 mg/dl • Subjects having thyroid disease • Evidence or history of clinically significant (in the judgment of the Investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies within the last 5 years • Subjects with HIV Positive • Subjects having history high alcohol intake (2 standard drinks per day) • Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent •Any other condition that in the opinion of the investigator, would adversely affect the subjects ability to complete the study or its measures •Subjects participated in any clinical study within thirty (30) days prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from the baseline to the end of the Supplement period in:â?¢ Muscle strength ( It will be measured by 1-RM in bench Press and leg Press) and â?¢ Muscular Endurance (It will be measured by total number of repetitions and weight lifted via leg extensions) Timepoint: Day 7, 21,35 and 49 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from the baseline to the end of the supplement period in: â?¢ Measurement in arm circumference (muscle size) â?¢ Change in Body-composition analysis by DEXA (Day 7 and Day 49) â?¢ Change in Serum biomarkers like Lactate (It will be assessed at rest (pre-exercise) and after cessation (post exercise) of exercise (Day-7 and Day 49) â?¢ Change in Serum biomarkers like IGF-1, IGFBP-3 and testosterone post exercise (Day 7 and Day 49) Timepoint: Day 7 and 49 | — |
Countries
India
Contacts
Public ContactSanjib Kumar Panda
Laila Nutraceuticals
Outcome results
None listed